About
Our journey
Key milestones on our journey
Abcam was established in 1998 by Jonathan Milner, David Cleevely and Tony Kouzarides in Cambridge, UK. Their mission was to source and sell online the best research antibodies in the world, together with the most comprehensive data, fast delivery, helpful customer service and technical support.
Today, with over 20 years of experiences, facilities in Europe, USA and Asia and customers in over 130 countries, we are a leading global proteomics pioneer that identifies, develops, and manufactures quality biological, protein, and custom cell engineering tools to the life science research and clinical communities.
2018
Agreement signed with Roche covering Spring Bioscience portfolio of over 750 products
Number of recombinant RabMAb antibodies available surpasses 13,000
2019
Calico Biolabs acquired (custom rabbit monoclonal antibody) capabilities
EdiGene acquired (cell line and lysate portfolio
2020
Cancer Research UK – custom partnership to accelerate cancer research
Marker Gene Technologies acquired (biology and organic chemistry)
Applied StemCell acquired (cell engineering and gene editing)
Expedeon acquired proteomics and immunology (conjugation)
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
abcam.comabcam.co.jp
abcam.cn
© Abcam plc. all rights reserved.
Abcam plc is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
Website by FisherPaul